Tocagen Announces Presentations at the AANS/CNS Joint Section on Tumors

Tocagen to Present Updated Interim Results from Studies Evaluating Toca 511 & Toca FC at the American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors

SAN DIEGO, – (April 30, 2015) — Tocagen Inc., a clinical-stage immuno-oncology company, today announced updated interim results from ongoing investigational studies of Toca 511 in combination with Toca FC will be presented by two principal investigators at the 11th Biennial Satellite Symposium of the American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors, to be held May 1-2, 2015, in Washington, D.C.

Details of the presentations are as follows:

Title: Surgical Trial Results: Tocagen
Date and Time: Saturday, May 2, at 2:48 p.m. ET
Presented By: Manish K. Aghi, M.D., associate professor of neurological surgery at the University of California, San Francisco

Title: Administration of Toca 511 to Subjects with Recurrent HGG Undergoing Repeat Resection
Date and Time: Saturday, May 2, at 4:48 p.m. ET
Presented By: Michael A. Vogelbaum, M.D., Ph.D., professor of neurosurgery at the Cleveland Clinic

About Toca 511 & Toca FC

Toca 511 & Toca FC is being investigated in four clinical trials in patients with recurrent high grade glioma, including glioblastoma. A pivotal Phase 2/3 study in patients with recurrent glioblastoma or anaplastic astrocytoma (the “Toca 5” study) is anticipated to initiate in 2015. The combination of Toca 511 & Toca FC is designed to break immune tolerance to the tumor using a combination of mechanisms. Toca 511, a retroviral replicating vector (RRV), delivers a prodrug-activating gene selectively to cancer cells. Then the prodrug-activating enzyme produced in the cancer cell is designed to activate orally administered Toca FC, an investigational extended-release formulation of 5-fluorocytosine (5-FC), into a powerful antimetabolite, 5 FU, which kills the infected cancer cell and neighboring 5-FU sensitive tumor cells. Glioma cells and myeloid derived suppressor cells in the tumor are known to be sensitive to 5-FU. In animal models, the production of 5-FU locally kills dividing tumor cells during each 5-FC cycle, which leads to durable and selective anticancer immune responses. Data from ongoing clinical trials show encouraging evidence for increased survival compared to historical benchmarks, excellent safety, and evidence to support the proposed mechanism of action.

About Tocagen Inc.

Tocagen is a clinical-stage biopharmaceutical company pursuing the discovery, development and commercialization of gene therapy products using a broadly applicable, cancer-selective immuno-oncology platform. These products leverage retroviral replicating vectors (RRVs) that selectively infect cancer cells. These therapies are designed to help patients fight their cancer by locally activating their immune system selectively and broadly against their tumor associated antigens, with subsequent durable, systemic benefit. Tocagen’s lead program is entering late-stage clinical development for patients with recurrent high grade glioma (glioblastoma or anaplastic astrocytoma).

Tocagen has received grant support from leading brain cancer foundations, including Accelerate Brain Cancer Cure (ABC2), National Brain Tumor Society (NBTS), American Brain Tumor Association (ABTA), Musella Foundation and Voices Against Brain Cancer (VABC). For more information about Tocagen or Toca 511 please visit www.tocagen.com or www.clinicaltrials.gov using the identifier NCT01470794, NCT01156584, NCT01985256, or NCT02414165.

Media Contact:

Canale Communications
Monica May
monica@canalecomm.com
(619) 849-5383